Page last updated: 2024-11-05

oxophenarsine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

oxophenarsine: obsolete toxic arsenical for treatment of syphilis; useful against some neoplasms; major descriptor (64-83); on-line search ARSENICALS (64-83); Index Medicus search OXOPHENARSINE (64-83); structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10845
CHEBI ID134860
SCHEMBL ID162292
MeSH IDM0262496

Synonyms (33)

Synonym
maphersen
nsc-627903
nsc627903
oxofenarsina
phenarsen
oxophenarsinum [inn-latin]
oxyphenarsine
phenol, 2-amino-4-arsenoso-
brn 3235865
oxofenarsina [inn-spanish]
oxophenarsine [inn]
oxarsan
einecs 206-178-8
(3-amino-4-hydroxyphenyl)arsenous acid
3-amino-4-hydroxyphenylarsinoxide
2-amino-4-(oxoarsino)phenol hydrochloride
2-amino-4-arsenosophenol
maphersen.rtm.
oxophenarsine
oxophenarsine hydrochloride 3-amino-4-hydroxyphenyl-arsineoxide hydrochloride
nsc627725
2-amino-4-arsoroso-phenol
CHEBI:134860
2-amino-4-arsorosophenol
3-16-00-00994 (beilstein handbook reference)
306-12-7
qic740f43h ,
unii-qic740f43h
oxophenarsinum
SCHEMBL162292
3-amino-4-hydroxy-phenylarsinoxyd
DTXSID30184665
Q27287280
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (252)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990248 (98.41)18.7374
1990's2 (0.79)18.2507
2000's0 (0.00)29.6817
2010's1 (0.40)24.3611
2020's1 (0.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other272 (99.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]